Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (241-250 of 362) with videos related to

Pageof 37
Sort By:
JMIR Research Protocols|June 29, 2021
Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic DataCarole Bandiera, Evelina Cardoso, Isabella Locatelli, et al.
ESMO Open|August 30, 2017
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribersJosep Tabernero, Malvika Vyas, Rosa Giuliani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2024
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER TrialRoss A Soo, Urania Dafni, Ji-Youn Han, et al.
Future Oncology (London, England)|December 30, 2025
The first United Arab Emirates expert consensus recommendations for the diagnosis and management of early and advanced non-small cell lung cancerHumaid Al Shamsi, Nadia Abdelwahed, Hassan Jaafar, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerSolange Peters, Alice T Shaw, Benjamin Besse, et al.
The Lancet. Oncology|July 17, 2009
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trialRoger Stupp, Michael Mayer, Roger Kann, et al.
Lancet (London, England)|January 24, 2021
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trialPaul Baas, Arnaud Scherpereel, Anna K Nowak, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2023
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2020
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)Solange Peters, Enriqueta Felip, Urania Dafni, et al.
ESMO Open|February 14, 2018
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapyChristian Manegold, Alex Adjei, Federico Bussolino, et al.
Pageof 37

Showing results (241-250 of 362) with videos related to

Sort By:
Pageof 37
JMIR Research Protocols|June 29, 2021
Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic DataCarole Bandiera, Evelina Cardoso, Isabella Locatelli, et al.
ESMO Open|August 30, 2017
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribersJosep Tabernero, Malvika Vyas, Rosa Giuliani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2024
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER TrialRoss A Soo, Urania Dafni, Ji-Youn Han, et al.
Future Oncology (London, England)|December 30, 2025
The first United Arab Emirates expert consensus recommendations for the diagnosis and management of early and advanced non-small cell lung cancerHumaid Al Shamsi, Nadia Abdelwahed, Hassan Jaafar, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerSolange Peters, Alice T Shaw, Benjamin Besse, et al.
The Lancet. Oncology|July 17, 2009
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trialRoger Stupp, Michael Mayer, Roger Kann, et al.
Lancet (London, England)|January 24, 2021
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trialPaul Baas, Arnaud Scherpereel, Anna K Nowak, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2023
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2020
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)Solange Peters, Enriqueta Felip, Urania Dafni, et al.
ESMO Open|February 14, 2018
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapyChristian Manegold, Alex Adjei, Federico Bussolino, et al.
Pageof 37